283 related articles for article (PubMed ID: 26277488)
1. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking and dynamic simulation evaluation of Rohinitib - Cantharidin based novel HSF1 inhibitors for cancer therapy.
Agarwal T; Annamalai N; Khursheed A; Maiti TK; Arsad HB; Siddiqui MH
J Mol Graph Model; 2015 Sep; 61():141-9. PubMed ID: 26245696
[TBL] [Abstract][Full Text] [Related]
3. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
4. Experimentally guided structural modeling and dynamics analysis of Hsp90-p53 interactions: allosteric regulation of the Hsp90 chaperone by a client protein.
Blacklock K; Verkhivker GM
J Chem Inf Model; 2013 Nov; 53(11):2962-78. PubMed ID: 24191708
[TBL] [Abstract][Full Text] [Related]
5. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
Islam MA; Pillay TS
J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
J Biomol Struct Dyn; 2018 May; 36(6):1463-1478. PubMed ID: 28482755
[TBL] [Abstract][Full Text] [Related]
7. Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.
Dunna NR; Bandaru S; Akare UR; Rajadhyax S; Gutlapalli VR; Yadav M; Nayarisseri A
Curr Top Med Chem; 2015; 15(1):57-64. PubMed ID: 25579569
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
Sakkiah S; Thangapandian S; John S; Lee KW
Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
[TBL] [Abstract][Full Text] [Related]
9. Effective screening strategy using ensembled pharmacophore models combined with cascade docking: application to p53-MDM2 interaction inhibitors.
Xue X; Wei JL; Xu LL; Xi MY; Xu XL; Liu F; Guo XK; Wang L; Zhang XJ; Zhang MY; Lu MC; Sun HP; You QD
J Chem Inf Model; 2013 Oct; 53(10):2715-29. PubMed ID: 24050442
[TBL] [Abstract][Full Text] [Related]
10. A systematic methodology for large scale compound screening: A case study on the discovery of novel S1PL inhibitors.
Deniz U; Ozkirimli E; Ulgen KO
J Mol Graph Model; 2016 Jan; 63():110-24. PubMed ID: 26724452
[TBL] [Abstract][Full Text] [Related]
11. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
12. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
13. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
14. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
Park H; Kim YJ; Hahn JS
Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold.
Jia JM; Liu F; Xu XL; Guo XK; Jiang F; Cherfaoui B; Sun HP; You QD
Bioorg Med Chem Lett; 2014 Mar; 24(6):1557-61. PubMed ID: 24582477
[TBL] [Abstract][Full Text] [Related]
16. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain.
Kim HH; Hyun JS; Choi J; Choi KE; Jee JG; Park SJ
Sci Rep; 2018 Jan; 8(1):368. PubMed ID: 29321504
[TBL] [Abstract][Full Text] [Related]
17. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
18. Assessing the chemical diversity of an hsp90 database.
Audisio D; Messaoudi S; Ijjaali I; Dubus E; Petitet F; Peyrat JF; Brion JD; Alami M
Eur J Med Chem; 2010 May; 45(5):2000-9. PubMed ID: 20170986
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
20. Folding and binding energy of a calmodulin-binding cell antiproliferative peptide.
Almudallal AM; Saika-Voivod I; Stewart JM
J Mol Graph Model; 2015 Sep; 61():281-9. PubMed ID: 26310499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
